ABSTRACT | PDF

Guest Gallery II

End-of-life care for persons with Alzheimer’s disease

Maheshwar NathTripathi

Service Senior Resident, Department of Psychiatry, Institute of Medical Sciences, Banaras Hindu University (BHU)

Introduction Because of the rapidly increasing number of older adults with chronic disabling conditions and because of advancements in lifesaving technologies, end-of-life care has become a significant component of the health care system. Although end-of-life care is a relatively common option for patients with terminal cancer, it has become available only recently for patients with Alzheimer's disease.[1]

Considering the cultural, religious, and socioeconomic context the debate on end-of-life care is just beginning in India but has been going on in developed countries for some decades.

A strong sense of fatalism prevails on the subcontinent. It is not just limited to the Hindus, the dominant faith of the populace. 'Whatever God has willed' is also the professed attitude of many other faiths. Thus acceptance of fate rather struggle for an end is the prevalent attitude. However, it is not likely to remain so. With education will come sophistication and more demanding clientele, who are likely to ask the question 'Isn't there anything else that can be done?'

When a person with Alzheimer's disease is in the very late stages of the disease, the focus should be on quality of life and comfort, rather than on length of life and treatment. This is the purpose of palliative care—to provide comfort and symptom relief, without the use of aggressive treatments, such as tube feeding, mechanical respiration, dialysis, and cardiopulmonary resuscitation, which often only prolong the suffering of the patient. Palliative (or comfort) care focuses on the whole person's needs—physical, emotional and spiritual.[2]

Clinical issues

The extent of the problem As of 2008, there are an estimated 30 million people with dementia worldwide. By 2050, it is projected that this figure will have increased to over 100 million. Much of the increase will be in developing countries. Already more than 60% of people with dementia live in developing countries, but by 2040 this will rise to 71%. The fastest growth in the elderly population is taking place in China, India, and their south Asian and western Pacific neighbours.[3]

General features Alzheimer's disease is the most common cause of dementia among persons older than 65 years. Although the course of Alzheimer's disease is predictable, the rate of disease progression is not. In two prospective studies median survival time for outpatients with Alzheimer's disease was largely dependent on age of onset and ranged from 3.3 to 9.3 years.[4,5] A prospective study demonstrated that comorbid conditions—such as diabetes, congestive heart failure, and ischaemic heart disease—were associated with reduced survival of patients with Alzheimer's disease.[6]

The end stage of Alzheimer's disease may last as long as two to three years.[7] Patients in this stage have significantly reduced verbal output, have incontinence, have a decreased ability to ambulate, and require total assistance with activities of daily living.[8] Their ability to recognise once familiar people is significantly diminished. These patients are mostly bedridden. Multiple and painful joint contractures often develop.[9] Pneumonia, urinary tract infection, dehydration, malnutrition, and bedsores are commonly listed as causes of death.

Focus on comfort, not life extension Deciding not to use extreme measures to prolong life does not mean withholding all treatments. A person may continue to receive any necessary medications, for example, those for chronic conditions such as diabetes or high blood pressure as well as those that prevent pain and discomfort.

Pain Managing pain and discomfort requires daily monitoring and reassessment of subtle nonverbal signals. As many as 45 to 80 percent of nursing home patients have pain that contributes materially to functional impairment and decreased quality of life.[10] Pain becomes an especially challenging issue among patients with cognitive impairment.[11] Pain is often not identified and tends to be undertreated in long-term-care facilities and is also common among patients who require end-of-life care.[12]

One of the causes for inadequate pain control among patients with Alzheimer's disease is the difficulty in detecting and assessing intensity of pain. In one study of 158 nursing home patients, the 0-to-10 pain rating scale was grossly inadequate in measuring pain.[13] Pain Assessment in Advanced Dementia and Pain Assessment for the Dementing Elderly are recently published tools that were developed specifically for patients with Alzheimer's disease, but further research is needed to test their reliability and validity.[14,15]

Effective pain management may have important implications for improving quality of life among individuals with end-stage Alzheimer's disease. Acetaminophen can be safely used around the clock in this population, but there is a risk of hepatotoxicity with chronic use. Although nonsteroidal anti-inflammatory drugs often work well for these patients, clinicians should be aware that they have various side effects. Additionally, it is important for clinicians to know that nonsteroidal anti-inflammatory drugs have a low ceiling effect.

Opiate drugs, such as morphine, have no ceiling effect and have been shown to relieve all types of pain.[16] Also, opiate drugs are probably underused in the geriatric population and may be safer than other drug strategies that are used.[17] However, clinicians should be aware that opiate drugs can increase confusion among patients with end-stage Alzheimer's disease.

The transdermal fentanyl patch may be helpful among patients who are unable to swallow pills. However, because of the drug's extreme potency and the potential for overdose, it should not be used among elderly patients who are opiate naive or among those who are unaccustomed to the respiratory depression caused by opiates.[18] A nonnarcotic agent, tramadol, may be useful. Tramadol has the same potency as codeine, but it rarely causes respiratory depression.

Finally, the soothing properties of touch, massage, music, fragrance, and a loving voice can also reduce pain.

Neuropsychiatric symptoms In the later stages of Alzheimer's disease more than 50 percent of patients exhibit behavioural symptoms, such as aggression, combativeness, shouting, and disinhibition.[19,20] However, as patients approach the end stage of Alzheimer's disease, they typically become mute and apathetic. They may cry out for no clear reason, but agitation is generally no longer a challenge that the clinician has to deal with. If they become agitated, it is very important to rule out underlying physical disorders.

Antipsychotic drugs are the mainstay of treatment for psychotic symptoms and aggression in this population. High-potency agents, such as haloperidol, are effective in controlling behavioural symptoms. Second-generation antipsychotic agents can be used for the same purpose.

Although it can be difficult to diagnose depression among noncommunicative patients with end-stage Alzheimer's disease, the presence of mood swings with crying spells and irritability may be indicative of depression.[21] Selective serotonin reuptake inhibitors are preferred agents to use when treating depression and have a favourable side-effect profile.

Delirium Patients with end-stage Alzheimer's disease are susceptible to various medical conditions. Comorbid medical conditions and cognitive impairment are serious risk factors for the development of delirium.[22] This problem may go unnoticed among patients in this population, especially when they have no appreciable behavioural manifestations of delirium. However, delirium is commonly accompanied by a wide array of behavioural changes, such as aggression, hallucinations, delusions, anxiety, and reversed sleep cycle. These behavioural disturbances can be overwhelming to patients and caregivers. It is important to provide these patients comfort and safety by using psychopharmacologic and environmental interventions while their underlying medical conditions are treated. Behavioural symptoms generally respond well to antipsychotic agents, regardless of the cause of delirium. Soft restraints may be necessary to keep these patients in beds or to keep them from pulling out intravenous lines.

Food refusal Some patients with Alzheimer's disease resist or refuse to eat for many reasons. However, in end-stage Alzheimer's disease, dysphagia is common and can be a significant challenge to clinicians and caregivers.[23] Individuals in this stage may simply forget how to eat, or a loss of brain cells may cause impairment of the swallowing mechanisms. Some patients with end-stage Alzheimer's disease are apathetic and have no interest in eating at all. Many patients in this stage may need assistance with much cueing or total feeding. Choking can be prevented by avoiding thin liquids, giving boluses of food with sufficient moisture, and keeping patients in a sitting position.[24]

Enteral (tube) feeding is inevitably addressed when patients with end-stage Alzheimer's disease stop eating or experience significant difficulty swallowing. A review of existing literature by Finucane and associates [25] concluded that there was no evidence that tube feeding among these patients prevents aspiration pneumonia, prolongs life, reduces incidence of pressure sores or infections, improves function, or provides palliation.

Caregivers' perspectives on end-of-life care Alzheimer's disease is a chronic process of gradual deterioration of cognitive ability. While this is clearly a tragedy for the individual and the family, the prolonged nature of the disease allows the clinician an opportunity to plan for progressive stages of the disease including the final stages of care. Clinicians should discuss with family members choices to be made at the end of life in Alzheimer's disease care and work with the family to ensure these wishes are followed. The geriatric psychiatrist plays a central role in these discussions.[26]

Settings For the past century, nursing homes and hospitals have increasingly become the site of death. Approximately half of all Americans who live to the age of 65 years will enter a nursing home before they die, and 20 percent will die there.[27] However, because nursing home care is more focused on restorative services, the palliative needs of persons with end-stage Alzheimer's disease in nursing homes are not adequately managed.[28] Additionally, a shortage of nursing staff and high rates of staff turnover are most likely to negatively affect the quality of end-of-life care in nursing homes.[28]

In an extensive survey of family members of 1,578 decedents, Teno and colleagues[29] concluded that many people dying in nursing homes or hospitals have unmet needs for symptom amelioration, communication with a physician, emotional support, and respectful attention. Also, they found that family members of decedents who received care at home with hospice services had fewer concerns about the amount of emotional support that was provided to the patients.

End-stage decisions Multiple issues can be addressed with the caregivers of persons with end-stage Alzheimer's disease in a manner consistent with their values, preferences, culture, educational level, and the patient's abilities. Ideally, patients have already prepared advance directives and a living will and appointed durable power of attorney before the onset of dementia. When these advance directives are unavailable, clinicians should help caregivers think through the relevant issues and come to their own decisions. These issues can be best addressed with caregivers in terms of the outcomes of various treatment options, goals of medical care, and risks. Clinicians need to be clear and direct, avoid medical jargon, and be empathic with caregivers' feelings. It is important to assure caregivers that their loved ones will receive supportive measures, even if caregivers decide not to opt for acute medical interventions.[1]

Emotional support Caregivers of persons with Alzheimer's disease experience stressful demands, especially because of the length of time that care is required, the behavioural symptoms of patients, and the severity of decline of patients during the course of the illness.[30] Insufficient attention has been given to how end-of-life care affects caregivers or to caregivers' responses to the death of the patient. A study conducted by Schulz and associates[31] indicated that caregivers needed intervention, and support services were needed most often immediately before the patient's death.

Caregivers of persons with Alzheimer’s disease may feel a variety and range of emotions – from relief and guilt to sadness and peace. These are all normal feelings and it is common to feel some guilt at experiencing a sense of relief at the person's death. Caregivers may need help in resuming their own lives after the patient's death. Psychiatrists who are called in as consultants or who have a long-term relationship with the patient or caregiver are uniquely positioned to assist the caregiver with his or her emotional needs that are associated with end-of-life care or the patient's demise.[32,33] Geriatric psychiatrists can play a central role in assisting families in managing end-of-life care in Alzheimer's disease.

Conclusion End-of-life care for individuals with end-stage Alzheimer's disease is increasingly important because of the rising number of patients with this disease. However, there are barriers to providing high-quality end-of-life care. Regardless of where persons with end-stage Alzheimer's disease receive care, health care systems and clinicians should make efforts to ameliorate the suffering of patients with this disease and their caregivers.

In India there is no clarity on the legality of standard palliative techniques[34] for the patients with AD though we hold the same value of respect for human dignity like developed countries but may express it differently.

References
1. Kye Y. Kim, M.D., Paul A. Yeaman, B.S. and Reba L. Keene, Practical Geriatrics: End-of-Life Care for Persons with Alzheimer's Disease. Psychiatr Serv 56:139-141, February 2005.
2. Practice guidelines for the treatment of patients with Alzheimer's disease and other dementias of late life: American Psychiatric Association. American Journal of Psychiatry 154(suppl 5):S28-S32, 1997
3. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L et al,. Global prevalence of dementia: A Delphi consensus study. The Lancet 2005; 366:2112– 2117.
4. Walsh B, Welch HG, Larson EB. Survival of outpatients with Alzheimer type dementia. Annals of Internal Medicine 1990; 113: 429–434.
5. Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. New England Journal of Medicine 2001; 344: 1111–1116.
6. Larson EB, Shadlen MF, Wang L, et al. Survival after initial diagnosis of Alzheimer's disease. Annals of Internal Medicine 2004; 140:501–509.
7. Brookmeyer R, Corrada MM, Curriero FC, et al. Survival following a diagnosis of Alzheimer's disease. Archives of Neurology 2002; 59:1764–1767.
8. Reisberg G, Ferris S, DeLeon M, et al. The global deterioration scale for assessment of primary degenerative dementia. American Journal of Psychiatry 1982; 139:1136–1139.
9. Souren LE, Franssen EH, Reisberg B. Contractures and loss of function in patients with Alzheimer's disease. Journal of the American Geriatrics Society 1995; 43:650–655.
10. Ferrell BA: Pain evaluation and management in the nursing home. Annals of Internal Medicine 1995; 123:681–687.
11. Ferrell BA, Ferrell BR, Rivera L. Pain in cognitively impaired nursing home patients. Journal of Pain and Symptom Management 1995; 10:591–598.
12. Moss MS, Braunschweig H, Rubinstein RL: Terminal care for nursing home residents with dementia. Alzhemer's Care Quarterly 2002; 3:233–246.
13. Weiner D, Peterson B, Ladd K, et al: Pain in nursing home residents: an exploration of prevalence, staff perspectives, and practical aspects of measurement. Clinical Journal of Pain 1999; 15:92–101.
14. Warden V, Hurley AC, Volicer L: Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. Journal of the American Medical Directors Association 2003; 4:9–15.
15. Vilaneuva MR, Smith TL, Erickson JS, et al: Pain assessment for the dementing elderly (PADE): reliability and validity of a new measure. Journal of the American Medical Directors Association 2003; 4:1–8.
16. Portenoy RK: Opiate therapy for chronic noncancer pain: can we get past the bias? American Pain Society Bulletin1991; 1:4–7.
17. Ferrell BA: Managing pain and discomfort in older adults near the end of life. Annals of Long-Term Care 2004; 12:49–55.
18. Ferrell BA: Pain evaluation and management, in Medical Care of the Nursing Home Resident. Edited by Besdine RW, Rubenstein LZ, Snyder L. Philadelphia, American College of Physicians, 1996.
19. Eisdorfer C, Cohen D, Paveza GJ, et al: An empirical evaluation of the Global Deterioration Scale for staging Alzheimer's disease. American Journal of Psychiatry 1992; 149:190–194.
20. Mega MS, Cummings JL, Fiorello T, et al: The spectrum of behavioural changes in Alzheimer's disease. Neurology 1996; 46:130–135.
21. Volicer L: Care at the end of life. Alzheimer's Care Quarterly 2001; 2:59–66.
22. Elie M, Cole M, Primeau F, et al: Delirium risk factors in elderly hospitalised patients. Journal of General Internal Medicine1998; 13:204–212.
23. Volicer L, Seltzer B, Rheaume Y, et al: Progression of Alzheimer-type dementia in institutionalised patients: a cross-sectional study. Journal of Applied Gerontology 1987; 6:83–94.
24. Mahoney EK, Volicer L, Hurley AC: Food refusal, in Management of Challenging Behaviours in Dementia. Baltimore, Health Professions Press, 2000.
25. Finucane TE, Christmas C, Travis K: Tube feeding in patients with advanced dementia: a review of the evidence. JAMA 1999; 282:1365–1370.
26. Kettl P. Helping families with end-of-life care in Alzheimer's disease. J Clin Psychiatry 2007; 68:445-50.
27. Zerzan J, Stearns S, Hanson L: Access to palliative care and hospice in nursing homes. JAMA 2000; 284:2489–2494.
28. Aupperle PM, MacPhee ER, Strozeski JE, et al: Hospice use for the patient with advanced Alzheimer's disease: the role of the geriatric psychiatrist. American Journal of Alzheimer's Disease and Other Dementias 2004; 19:94–104.
29. Teno JM, Clarridge BR, Casey V, et al: Family perspectives on end-of-life care at the last place of care. JAMA 2004; 291:88–93.
30. Hurly AC, Volicer L. Alzheimer's disease: "It's OK, Mama, if you want to go, it's OK." JAMA 2002; 288:2324–2331.
31. Schulz R, Mendelsohn AB, Haley WE, et al: End-of-life care and the effects of bereavement on family caregivers of persons with dementia. New England Journal of Medicine 2003; 349:1936–1942.
32. Spiess JL, Northcott CJ, Offsay JD, et al: Palliative care: something else we can do for our patients. Psychiatric Services 2002; 53:1525–1529.
33. Holt J: Psychiatry and spirituality at the end of life: a case report. Psychiatric Services 2004; 55:618–622.
34. Mani RK. Limitation of life support in the ICU: ethical issues relating to end of life care. Indian J Crit Care Med 2003;7:112–117.

 

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Nach oben